STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Vaccines Review Article

The Power of Genetic Engineering in Revolutionizing Vaccines

  1. Ramdas Bhat Department of Pharmacology,Srinivas College of Pharmacy
  2. Preeti Shanbhag Department of Pharmacology,Srinivas College of Pharmacy
  3. Sinchana S Bhat Department of Pharmacology,Srinivas College of Pharmacy
  4. Megha M Department of Pharmacology,Srinivas College of Pharmacy
  5. Kavana D K Department of Pharmacology,Srinivas College of Pharmacy
  6. Rithin K Department of Pharmacology,Srinivas College of Pharmacy

Abstract

Genetic engineering techniques, including recombinant subunit, viral vector, and nucleic acid vaccines have transformed the landscape of vaccine development. These novel approaches offer precise antigen design, enhanced safety profiles, and rapid adaptability to emerging pathogens. Key advantages include improved efficacy through targeted immune responses, increased safety due to the absence of live pathogens, and the ability to modify vaccines to address new variants or diseases quickly. Notable success stories, such as the hepatitis B vaccine and the recent mRNA-based COVID-19 vaccines, demonstrate the transformative potential of this technology. However, challenges persist in areas of production scalability, regulatory approval processes, and public perception. The effectiveness and broad acceptance of genetically modified vaccinations depend on resolving these problems. The field holds promising prospects for personalized vaccines tailored to individual genetic profiles, universal flu vaccines targeting conserved viral regions, and therapeutic vaccines for chronic diseases. As genetic engineering techniques continue to evolve, they have the potential to dramatically reshape our approach to disease prevention and treatment. This review explores the transition from conventional vaccine approaches to genetically engineered methods, examining their advantages, challenges, and future prospects. It aims to provide a comprehensive overview of how genetic engineering is revolutionizing vaccine development, offering hope for more effective, accessible, and adaptable solutions to global health challenges in the 21st century and beyond.

Keywords

References (45)

  1. History of Smallpox | Smallpox | CDC [Internet]. www.cdc.gov. 2019.[cited 2024] Available from: https://www.cdc.gov/smallpox/history/history.html#:~:text=The%20basis%20for%20vaccination%20began.
  2. Montero DA, Vidal RM, Velasco J, Carreño LJ, Torres JP, Benachi O. MA, et al. Two centuries of vaccination: historical and conceptual approach and future perspectives. Frontiers in Public Health. 2024;11. doi:10.3389/fpubh.2023.1326154
  3. Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B Vaccines. The Journal of Infectious Diseases. 2021;224(Supplement_4):S343-S351. doi:10.1093/infdis/jiaa668
  4. Al Fayez N, Nassar MS, Alshehri AA, Alnefaie MK, Almughem FA, Alshehri BY, et al. Recent Advancement in mRNA Vaccine Development and Applications. Pharmaceutics. 2023;15(7):1972. doi:10.3390/pharmaceutics15071972
  5. Rando HM, Lordan R, Lee AJ, Naik A, Wellhausen N, Sell E, et al. Application of Traditional Vaccine Development Strategies to SARS-CoV-2. mSystems. 2023;8(2). doi:10.1128/msystems.00927-22
  6. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biology. 2012;9(11):1319-1330. doi:10.4161/rna.22269
  7. Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021;184(6):1589-1603. doi:10.1016/j.cell.2021.02.030
  8. Types of Vaccine. India Science, Technology & Innovation - ISTI Portal [Online]. indiascienceandtechnology.gov.in. Available from: https://www.indiascienceandtechnology.gov.in/covid-19-vaccine/types-vaccine.
  9. Minor PD. Live attenuated vaccines: Historical successes and current challenges. Virology. 2015;479-480:379-392. doi:10.1016/j.virol.2015.03.032
  10. Kennedy RB, Ovsyannikova IG, Palese P, Poland GA. Current Challenges in Vaccinology. Frontiers in Immunology. 2020;11. doi:10.3389/fimmu.2020.01181
  11. Kozak M, Hu J. DNA Vaccines: Their Formulations, Engineering and Delivery. Vaccines. 2024;12(1):71. doi:10.3390/vaccines12010071
  12. Daniali M, Mousavi T, Abdollahi M. Biological Products in Medicine. In: Encyclopedia of Toxicology. 2nd edition. Amsterdam: Elsevier; 2024. 117–132.
  13. Jain S, Venkataraman A, Wechsler ME, Peppas NA. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Advanced Drug Delivery Reviews. 2021;179:114000. doi:10.1016/j.addr.2021.114000
  14. Matić Z, Šantak M. Current view on novel vaccine technologies to combat human infectious diseases. Applied Microbiology and Biotechnology. 2021;106(1):25-56. doi:10.1007/s00253-021-11713-0
  15. Ghattas M, Dwivedi G, Lavertu M, Alameh MG. Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines. 2021;9(12):1490. doi:10.3390/vaccines9121490
  16. Zahedipour F, Zahedipour F, Zamani P, Jaafari MR, Sahebkar A. Harnessing CRISPR technology for viral therapeutics and vaccines: from preclinical studies to clinical applications. Virus Research. 2024;341:199314. doi:10.1016/j.virusres.2024.199314
  17. Bezbaruah R, Chavda VP, Nongrang L, Alom S, Deka K, Kalita T, et al. Nanoparticle-Based Delivery Systems for Vaccines. Vaccines. 2022;10(11):1946. doi:10.3390/vaccines10111946
  18. Khan S, Ullah MW, Siddique R, Nabi G, Manan S, Yousaf M, et al. Role of Recombinant DNA Technology to Improve Life. International Journal of Genomics. 2016;2016:1-14. doi:10.1155/2016/2405954
  19. Murray K, Stahl S, Ashton-Rickardt PG. Genetic engineering applied to the development of vaccines. Philosophical Transactions of the Royal Society of London. B, Biological Sciences. 1989;324(1224):461-476. doi:10.1098/rstb.1989.0060
  20. Hogan MJ, Pardi N. mRNA Vaccines in the COVID-19 Pandemic and Beyond. Annual Review of Medicine. 2022;73(1):17-39. doi:10.1146/annurev-med-042420-112725
  21. Deng S, Liang H, Chen P, Li Y, Li Z, Fan S, et al. Viral vector vaccine development and application during the COVID-19 pandemic. Vaccines. 2022;10(7):1450. doi:10.3390/
  22. Joudeh AI, Lutf AQ, Mahdi S, Tran G. Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review. Vaccine. 2023;41(26):3801-3812. doi:10.1016/j.vaccine.2023.05.048
  23. Lee J, Arun Kumar S, Jhan YY, Bishop CJ. Engineering DNA vaccines against infectious diseases. Acta Biomaterialia. 2018;80:31-47. doi:10.1016/j.actbio.2018.08.033
  24. Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunologic Research. 2022;70(3):289-315. doi:10.1007/s12026-022-09265-0
  25. McCullers JA, Dunn JD. Advances in vaccine technology and their impact on managed care. Pharm Ther. 2008;33(1):35.
  26. Zhao H, Zhou X, Zhou YH. Hepatitis B vaccine development and implementation. Human Vaccines & Immunotherapeutics. 2020;16(7):1533-1544. doi:10.1080/21645515.2020.1732166
  27. Flores JE, Thompson AJ, Ryan M, Howell J. The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma. Vaccines. 2022;10(5):793. doi:10.3390/vaccines10050793
  28. Al-Busafi SA, Alwassief A. Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030. Vaccines. 2024;12(3):288. doi:10.3390/vaccines12030288
  29. Dhalaria P, Kapur S, Singh AK, Verma A, Priyadarshini P, Taneja G. Potential impact of rotavirus vaccination on reduction of childhood diarrheal disease in India: An analysis of National Family Health Survey-5. Vaccine: X. 2023;14:100319. doi:10.1016/j.jvacx.2023.100319
  30. Cárcamo-Calvo R, Muñoz C, Buesa J, Rodríguez-Díaz J, Gozalbo-Rovira R. The Rotavirus Vaccine Landscape, an Update. Pathogens. 2021;10(5):520. doi:10.3390/pathogens10050520
  31. Burnett E, Parashar U, Tate J. Rotavirus Vaccines: Effectiveness, Safety, and Future Directions. Pediatric Drugs. 2018;20(3):223-233. doi:10.1007/s40272-018-0283-3
  32. Chen WH, Strych U, Bottazzi ME, Lin YP. Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights. Expert Review of Vaccines. 2022;21(10):1405-1417. doi:10.1080/14760584.2022.2102484
  33. Pine M, Arora G, Hart TM, Bettini E, Gaudette BT, Muramatsu H, et al. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. Molecular Therapy. 2023;31(9):2702-2714. doi:10.1016/j.ymthe.2023.07.022
  34. Gomes-Solecki M, Arnaboldi PM, Backenson PB, Benach JL, Cooper CL, Dattwyler RJ, et al. Protective Immunity and New Vaccines for Lyme Disease. Clinical Infectious Diseases. 2019;70(8):1768-1773. doi:10.1093/cid/ciz872
  35. Cooper A, Sidaway A, Chandrashekar A, Latta E, Chakraborty K, Yu J, et al. A genetically engineered, stem-cell-derived cellular vaccine. Cell Reports Medicine. 2022;3(12):100843. doi:10.1016/j.xcrm.2022.100843
  36. Grohskopf LA. Prevention and control of seasonal influenza with vaccines: Recommendations of the advisory committee on immunization practices—United States, 2024–25 influenza season. MMWR. Recommendations and Reports. 2024;73.
  37. Vaccines. doi:10.3390/vaccines
  38. Park HJ, Bang YJ, Kwon SP, Kwak W, Park SI, Roh G, et al. Analyzing immune responses to varied mRNA and protein vaccine sequences. npj Vaccines. 2023;8(1). doi:10.1038/s41541-023-00684-0
  39. Vaccines. doi:10.3390/vaccines
  40. Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, et al. Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024. Clinical Infectious Diseases. 2024;82(3):e595-e603. doi:10.1093/cid/ciae405
  41. Brisse M, Vrba SM, Kirk N, Liang Y, Ly H. Emerging Concepts and Technologies in Vaccine Development. Frontiers in Immunology. 2020;11. doi:10.3389/fimmu.2020.583077
  42. Oude Blenke E, Örnskov E, Schöneich C, Nilsson GA, Volkin DB, Mastrobattista E, et al. The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case. Journal of Pharmaceutical Sciences. 2023;112(2):386-403. doi:10.1016/j.xphs.2022.11.001
  43. Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon. 2024;10(4):e26297. doi:10.1016/j.heliyon. e26297.
  44. Galagali PM, Kinikar AA, Kumar VS. Vaccine Hesitancy: Obstacles and Challenges. Current Pediatrics Reports. 2022;10(4):241-248. doi:10.1007/s40124-022-00278-9
  45. Petersen MB, Bor A, Jørgensen F, Lindholt MF. Transparent communication about negative features of COVID-19 vaccines decreases acceptance but increases trust. Proceedings of the National Academy of Sciences. 2021;118(29). doi:10.1073/pnas.2024597118